# Clinical Case Summary

## Patient Summary
**Patient**: Not specified **Age**: 10 **Sex**: Male **Date of Diagnosis**: July 2024 **Primary Cancer Type**: Brain cancer - DIPG (Diffuse Intrinsic Pontine Glioma) **Medical Diagnosis**: DIPG **Current Treatment Status**: Signs of treatment resistance/cancer progression with new treatment likely needed

## Treatment History
**Treatments**:
* Immunotherapy, Radiation, Clinical Trial

**Specific Interventions**:
* (08/2024-09/2024): Radiation
* (08/2024-09/2024): Optune
* (01/2025-02/2025): Radiation
* (01/2025-03/2025): Optune
* (03/2025): Radiation
* (06/11/2024): CAR-T clinical trial (GD2) infusion

## Molecular/Genetic Characteristics
**Biomarkers**:
* TP53: Likely Pathogenic Variant, p.I254_S260del (exon 7), c.761_781del21, 94% frequency
* H3F3A: Pathogenic Variant, p.K28M, c.83A>T, 76% frequency
* SMO: Amplified
* Microsatellite Instability (MSI): Stable
* Tumor Mutational Burden (TMB): Low (2 mutations/Mb)
* Loss of Heterozygosity (LOH): Equivocal - 12% of tested genomic segments exhibited LOH (assay threshold is â‰¥ 16%)
* MGMT Promoter Methylation: Unmethylated
* Fusion testing: Negative
* Germline pathogenic mutations: Negative

## Protein Expression and Immunohistochemistry
**Expression Status**:
* EGFR: No relevant expression
* HER2 (ERBB2): No relevant expression/Negative (0)
* PD-L1: No relevant expression
* VEGFR2: No relevant expression in tumor cells, strong staining in tumor-associated vessels
* HLA: Complete loss

## Additional Information
**Medications/Supplements**: Keppra, Piperlongume, Berberine, Ashwagandha, Green Tea Extract, Claritin, Perilyll Alcohol, 2DG, Vitamin D, SeaCare, Methioninase enzyme, Metformin topical cream, Honokiol, Lovastatin, Genistein, Chaga, Legasil, ONC201, ONC206

**Clinical Questions**
1. Additional recommendations for treatments
